Evaluation of the antineoplastic activity of mitoxantrone–l-carnitine combination therapy on an experimental solid form of ehrlich tumour in mice

Niang, Mohamed; Mĕlka, M; Stoklasová, A; Cerman, J; Tomšík, Pavel

doi:10.1016/j.phrs.2006.09.003

Cited by 7 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our previous study the effects of MX- L -carnitine were evaluated in a model of mice with STE [20]. We suggested that monotherapy with L -carnitine was ineffective at inhibiting tumour growth and even appeared to have a slight stimulatory effect.…”

Section: Discussionmentioning

confidence: 99%

“…We also reported in a recent study the effect of combining MX with L -carnitine (i.e. the non-acetylated form) on the growth of a solid form of Ehrlich tumour inoculated into mice, as well as on survival outcome [20]. In that study, 2 doses of MX (3 or 6 mg·kg –1 ) in combination with L -carnitine were administered to mice bearing the Ehrlich tumour.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Biochemical and Pharmacological Effects of Mitoxantrone and Acetyl-L-Carnitine in Mice with a Solid Form of Ehrlich Tumour

Niang¹,

Soukup²,

Živný

et al. 2011

Chemotherapy

Self Cite

View full text Add to dashboard Cite

Background: Dysfunction of the carnitine system in non-tumour tissue following anticancer therapy has been reported. In this setting, supplementation with carnitine derivatives might increase the general metabolic activity of normal cells so that they might better withstand the adverse effects of chemotherapy aimed at tumour cells. Here we investigated the effect of acetyl-L-carnitine (ALC) alone and in combination with the antineoplastic agent mitoxantrone (MX) in an animal cancer model. Methods: The effects of MX and MX-ALC were assessed based on gain or loss of body weight and on local growth of a solid form of Ehrlich tumour inoculated into mice. We also performed biochemical analyses like serum activities of some enzymes signalling the functioning of the liver, aspartate aminotransferase (AST), and alanine aminotransferase (ALT). Total protein, albumin and bilirubin were also determined in serum. Under favourable conditions, the Ehrlich tumour readily forms metastases, and this is the reason why we performed histological studies of samples of both the liver and heart in order to identify changes that may have mediated the observed effect of the treatment. In addition to those studies, the survival time of treated animals against controls was also noted. Results: MX monotherapy was associated with lower body weight gain, fewer metastases, smaller tumour size, and lower dissemination. ALC alone promoted survival, but had no potentiating effect on MX therapy in terms of survival. Serum biochemistry changes associated with MX-ALC treatment consisted of a significant (p < 0.05) increase in AST with MX at 6 or 9 mg·kg^–1 plus ALC 200 mg·kg^–1 and a significant (p < 0.05) reduction in total protein compared to the corresponding MX group; serum albumin and bilirubin remained unchanged. Conclusion: ALC in combination with MX, regardless of the dose of MX, led to higher occurrences of metastases with dissemination to the kidneys, lungs, heart, and mediastinum compared to MX treatment alone. These histological findings indicate that ALC is inappropriate to combine with MX in the treatment of a solid cancer. The protective effect of ALC in combination therapy with the cytostatic drug MX was not supported in this study by our findings that the agent did not improve the therapeutic outcomes of MX therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Biochemical and Pharmacological Effects of Mitoxantrone and Acetyl-L-Carnitine in Mice with a Solid Form of Ehrlich Tumour

Niang¹,

Soukup²,

Živný

et al. 2011

Chemotherapy

Self Cite

View full text Add to dashboard Cite

show abstract

“…In this way, carnitine could support the nutrition of normal cells and contribute to their protection against the detrimental effects of the cytostatic compound. In our previous study [12], two doses of MX (3 or 6 mg kg -1 ) in combination with LCAR (200 mg kg -1 ) were administered to mice bearing the solid form of Ehrlich tumor. The results of the abovementioned study, based on an index of relative hazard, suggested using a higher dose of both drugs.…”

Section: Discussionmentioning

confidence: 99%

“…We have previously reported [12] that therapeutic effects of MX-LCAR combination therapy on an experimental solid form of Ehrlich tumor in mice can be expected at high doses of both drugs, based on values calculated from an index of relative hazard. In this study, we investigated the effect of LCAR on the lethal toxicity of intravenous administration of single-doses of MX into mice.…”

Section: Introductionmentioning

confidence: 99%

Effect of L-carnitine against acute mitoxantrone toxicity in mice

et al. 2008

View full text Add to dashboard Cite

“…L-Carnitine: L-Carnitine is a natural metabolic drug that acts as a carrier molecule for long-chain fatty acids in mitochondria and generates energy. L-carnitine deficiency is associated with the accumulation of acyl CoA esters and disorders of intermediary metabolism (44). L-carnitine is reported to be effective in reducing fatigue in MS patients.…”

Section: List Of the Vitamins And Supplements Used For The Treatment mentioning

confidence: 99%

Supplement Therapy in Multiple Sclerosis: A Pharmacological View

Mohammadi

Rashidizad

Lashkari

et al. 2020

Avicenna J Pharm Res

View full text Add to dashboard Cite

Introduction Multiple sclerosis (MS), a severely debilitating disorder, is identified by progressive demyelination and axonal damage in the central nervous system (CNS). Although the underlying causes of the disease are unknown, it is accepted in general that MS starts when autoreactive T-cells penetrate the CNS to attack the nervous system (1). Several types of MS have been recognized, the most common of which is characterized by waxing and waning of signs and symptoms to produce a "relapsingremitting" clinical presentation. "Relapsing-remitting MS" affects 85% of MS patients (2). About 30% of these patients experience "secondary progressive MS" within a decade (3), a type with less inflammation and more neurodegeneration. "Primary progressive MS" is a distinct type of MS which is not obviously correlated with relapses and shows neurodegeneration without inflammatory change. The late-stage sequelae from advanced MS include permanent disability and death (4). Although the etiology of this autoimmune disorder is intricate, it has been suggested that both genetic susceptibility and non-genetic triggers have a role (5). Medicines used in MS are not completely functional and various side effects are reported by patients. Nowadays, complementary and alternative medicines (CAMs) are used increasingly and patients tend to use this kind of treatment. Having a healthy lifestyle and using CAM treatment can eliminate some of the symptoms and improve the quality of life in these patients. Many patients use CAM therapies to decrease their symptoms (6). This study attempted to investigate the use of herbal remedies and supplements in MS treatment to confirm or rule out the effectiveness or ineffectiveness of these supplementary medicines. Herbal and Supplement Products for the Treatment of Multiple Sclerosis Using herbal products and supplements in patients with MS is a new area for the research (7). Herbal bioactive compounds like flavonoids, lipoic acid, vitamin C, and so on are the most efficient therapies in relapsing and progressive forms of MS because of the neuroprotective and anti-inflammatory properties (8). Moreover, it should be noted that polyphenols, terpenes, alkaloids, anthocyanidin glycosides, plant amines, volatile oils, and so on play a noticeable role in the treatment of MS (9). Several studies investigated the role of minerals, vitamins, and other related supplements in symptomatic and

show abstract

Evaluation of the antineoplastic activity of mitoxantrone–l-carnitine combination therapy on an experimental solid form of ehrlich tumour in mice

Cited by 7 publications

References 18 publications

Biochemical and Pharmacological Effects of Mitoxantrone and Acetyl-L-Carnitine in Mice with a Solid Form of Ehrlich Tumour

Biochemical and Pharmacological Effects of Mitoxantrone and Acetyl-L-Carnitine in Mice with a Solid Form of Ehrlich Tumour

Effect of L-carnitine against acute mitoxantrone toxicity in mice

Supplement Therapy in Multiple Sclerosis: A Pharmacological View

Contact Info

Product

Resources

About